Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
CN101346376A | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Jul, 2011
(11 years ago) | |
CN101212903A | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
CN101212903B | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
CN102245182A | VIIV HLTHCARE | Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate |
Dec, 2029
(6 years from now) | |
CN102245182B | VIIV HLTHCARE | Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis |
Dec, 2029
(6 years from now) | |
IN201838011858A | VIIV HLTHCARE | Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors |
Dec, 2029
(6 years from now) | |
IN373756B | VIIV HLTHCARE | Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors |
Dec, 2029
(6 years from now) | |
EP1852434A4 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
EP1852434B1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
EP1852434A1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
EP3372281A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2527007B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3284520A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3284520B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3187225B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3187225A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2527007A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3045206B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3045206A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3372281B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2465580B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117B8 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2465580A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1950212B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(3 years from now) | |
EP1950212A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(3 years from now) | |
EP1950212A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(3 years from now) | |
EP2376080A4 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(6 years from now) | |
EP2376080B1 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(6 years from now) | |
EP2376080A1 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(6 years from now) |
Market Authorisation Date: 22 August, 2014
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8129385 | VIIV HLTHCARE | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness |
Oct, 2027
(4 years from now) | |
US9242986 | VIIV HLTHCARE | Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates |
Dec, 2029
(6 years from now) | |
CN101346376A | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Jul, 2011
(11 years ago) | |
CN101212903A | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
CN101212903B | VIIV HLTHCARE | Polycyclic Carbamoyl Pyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
CN102245182A | VIIV HLTHCARE | Synthesis Of Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediate |
Dec, 2029
(6 years from now) | |
CN102245182B | VIIV HLTHCARE | Carbamoyl Pyridone Hiv Integrase Inhibitors And Intermediates For Synthesis |
Dec, 2029
(6 years from now) | |
IN201838011858A | VIIV HLTHCARE | Process For The Preparation Of Carbamoylpyridone Hiv Integrase Inhibitors |
Dec, 2029
(6 years from now) | |
IN373756B | VIIV HLTHCARE | Process For The Preparation Of Carbamoylpyrid One Hiv Integrase Inhibitors |
Dec, 2029
(6 years from now) | |
EP1852434A4 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
EP1852434B1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
EP1852434A1 | VIIV HLTHCARE | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibiting Activity |
Feb, 2026
(3 years from now) | |
EP3372281A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2527007B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3284520A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3284520B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3187225B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3187225A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2527007A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3045206B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3045206A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP3372281B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2465580B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117B8 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1874117A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP2465580A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivatives Having Hiv Integrase Inhibitory Activity |
Apr, 2026
(3 years from now) | |
EP1950212B1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(3 years from now) | |
EP1950212A4 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(3 years from now) | |
EP1950212A1 | VIIV HLTHCARE | Polycyclic Carbamoylpyridone Derivative Having Inhibitory Activity On Hiv Integrase |
Oct, 2026
(3 years from now) | |
EP2376080A4 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(6 years from now) | |
EP2376080B1 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(6 years from now) | |
EP2376080A1 | VIIV HLTHCARE | Synthesis Of Carbamoylpyridone Hiv Integrase Inhibitors And Intermediates |
Dec, 2029
(6 years from now) |
Market Authorisation Date: 30 March, 2022
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic